Table 1 Demographic and clinical characteristics of the 190 study participants
Age, yrs., M (SD) | 59.9 (11.2) |
Sex (men), n (%) | 157 (82.6) |
Education level | |
 High, n (%) | 36 (18.9) |
 Medium, n (%) | 136 (71.6) |
 Low, n (%) | 18 (9.5) |
Living with someone, n (%) | 138 (72.6) |
Charlson comorbidity index, M (SD) | 1.80 (1.20) |
Positive history of hypertension, n (%) | 98 (51.6) |
Positive history of high cholesterol, n (%) | 86 (45.3) |
Positive history of depression, n (%) | 54 (28.4) |
Body mass index, kg/m2, M (SD) | 27.7 (4.6) |
Smoking status | |
 Current smoker, n (%) | 83 (43.7) |
 Former smoker, n (%) | 50 (26.3) |
 Never smoker, n (%) | 57 (30.0) |
Alcohol consumption (drinks per week) | |
 Abstainers, n (%) | 33 (17.4) |
 Moderate drinkers, n (%) | 147 (77.4) |
 Heavy drinkers, n (%) | 10 (5.3) |
Physical activity (number of times per week) | |
 3–7, n (%) | 49 (25.8) |
 1–2, n (%) | 52 (27.4) |
  < 1, n (%) | 89 (46.8) |
Previous myocardial infarction, n (%) | 20 (10.5) |
Previous percutaneous coronary intervention | 27 (14.2) |
Previous coronary artery bypass surgery | 5 (2.6) |
Type of confirmed acute infarction | Â |
ST-elevation myocardial infarction, n (%) | 136 (71.6) |
Non-ST-elevation myocardial infarction, n (%) | 54 (28.4) |
Major coronary arteries with stenosis ≥50% (number), M (SD) | 1.93 (0.86) |
Left ventricular ejection fraction (angiography), %, M (SD) | 47. 6 (11.8) |
Vasopressant drugs at admission | |
 Epinephrine, n (%) | 9 (4.7) |
 Norepinephrine, n (%) | 6 (3.2) |
 Dobutamine, n (%) | 8 (4.2) |
 Dopamine, n (%) | 1 (0.5) |
Antithrombotic therapy at admission | |
 Aspirin, n (%) | 190 (100) |
 Clopidogrel, n (%) | 57 (30.0) |
 Prasugrel, n (%) | 99 (52.1) |
 Ticagrelor, n (%) | 80 (42.1) |
 Fondaparinux, n (%) | 154 (81.1) |
 Unfractioned heparin, n (%) | 145 (76.3) |
 Low molecular weight heparin, n (%) | 13 (6.8) |
 Bivalirudin, n (%) | 2 (1.1) |
 Abciximab, n (%) | 46 (24.2) |
 Thrombolysis, n (%) | 2 (1.1) |
Beta-blocker therapy at admission, n (%) | 173 (91.1) |
Regular use of glucocorticoids, n (%) | 13 (6.8) |
Global Registry of Acute Coronary Events risk score, M (SD) | 107 (27) |
Acute distress during myocardial infarction, M (SD) | 6.23 (1.40) |
Sleep difficulties total, M (SD) | 1.53 (1.29) |
Difficulties initiating sleep, M (SD) | 1.24 (1.62) |
Nighttime awakenings, M (SD) | 2.53 (2.10) |
Difficulties maintaining sleep, M (SD) | 1.17 (1.68) |
Nonrestorative sleep, M (SD) | 1.17 (1.67) |
High risk of obstructive sleep apnea, n (%) | 77 (40.5) |